Anicom Holdings, Inc. (8715) AI Stock Analysis

• Market Cap: ¥100.13B
• Dividend Yield: 0.82%
• Average Volume (3M): 408.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 11.18%
• EPS Growth: -16.50%
• Country: JP
• Employees: 933
• Sector: Financial
• Sector Strength: 70
• Industry: Insurance - Property & Casualty
• EPS (TTM): 0.03
• Shares Outstanding: 74,939,160
• 10 Day Avg. Volume: 354,520
• 30 Day Avg. Volume: 408,940
• PEG Ratio: 0.54
• Price to Book (P/B): 1.47
• Price to Sales (P/S): 0.61
• P/FCF Ratio: 7.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 31.2
• Revenue Forecast (FY): ¥73.95B

• Rating: 72 Outperform
• Price Target: ¥1,484.00 ▲(40.26% Upside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is primarily driven by strong financial performance (rapid revenue growth, improving profitability, and exceptional free cash flow) and an established uptrend. This is offset by overbought technical readings that raise pullback risk and a rich valuation (high P/E with a modest dividend yield).

Positive Factors

Revenue Growth

Sustained 35.2% revenue growth demonstrates durable expansion of premium income and market penetration in the pet insurance niche. Over the medium term this enlarges the revenue base, supports economies of scale in claims handling and distribution, and underpins reinvestment capacity.

Cash Generation

Exceptional free cash flow growth (242.4%) with strong cash conversion ratios (OCF/NetIncome 1.36; FCF/NetIncome 0.91) signals durable cash-generative underwriting and operating performance. Robust cash flow supports reserve funding, capex, and reduced reliance on external financing.

Balance Sheet Strength

A low debt-to-equity ratio (0.36) and solid equity position reflect conservative leverage and financial flexibility. This balance sheet strength provides resilience against claim volatility, preserves capacity to invest in growth initiatives, and reduces solvency risk over time.

Negative Factors

EBIT Margin Pressure

A decline in EBIT margin points to rising operating or underwriting costs that could persist. If cost pressures continue, the company may face sustained margin compression requiring pricing adjustments or efficiency gains, which could temper long-term profitability despite revenue growth.

Earnings Volatility

A roughly 32% decline in EPS signals material earnings volatility despite top-line gains. Such swings reduce predictability of profits and complicate capital allocation, reserve planning, and consistent shareholder returns, making financial outcomes less reliable over multiple quarters.

Concentrated Business Model

Heavy concentration in pet insurance narrows revenue diversification and ties company fortunes to sector-specific dynamics (veterinary cost inflation, claim frequency, regulation). This specialization increases exposure to idiosyncratic shocks and limits risk diversification versus broader P&C peers.

Anicom Holdings, Inc. Business Overview & Revenue Model

Company Description

Anicom Holdings, Inc., through its subsidiaries, provides pet insurance products and services in Japan. It offers animal hospital management, insurance agency, and paid employment placement services; and clinical research services in animal medicine field. In addition, the company plans, develops, and operates internet services related to pets. Anicom Holdings, Inc. was founded in 2000 and is based in Tokyo, Japan.

How the Company Makes Money

Anicom Holdings makes money primarily through its pet insurance operations. The core revenue stream is insurance-related income generated from policyholders (e.g., premiums paid for pet insurance coverage). The group also earns revenue associated with administering insurance contracts and handling claims, where profitability is influenced by factors such as the volume of in-force policies, pricing, and the balance between premium income and claims paid for veterinary treatment. Additional earnings can come from investment/asset management of insurance-related funds (typical for insurers), where investment income contributes to overall results, but specific allocations or magnitudes are null. Information on material partnerships, distribution agreements, or non-insurance segment revenues is null.

Anicom Holdings, Inc. Financial Statement Overview

Summary

Strong fundamentals supported by 35.2% revenue growth, improved net profit margin (5.37%), and exceptionally strong cash flow (free cash flow up 242.4% with solid cash conversion). Balance sheet leverage is prudent (debt-to-equity 0.36), though a slightly lower EBIT margin suggests some cost pressure.

Income Statement

Anicom Holdings, Inc. has demonstrated strong revenue growth with a 35.2% increase in the latest year, indicating robust business expansion. The net profit margin improved to 5.37%, reflecting enhanced profitability. However, the EBIT margin decreased slightly, suggesting potential cost management challenges.

Balance Sheet

The company maintains a healthy debt-to-equity ratio of 0.36, indicating prudent financial leverage. The return on equity stands at 11.57%, showcasing effective utilization of shareholder funds. The equity ratio is solid, reflecting a stable financial position.

Cash Flow

Anicom Holdings, Inc. exhibits impressive free cash flow growth of 242.4%, highlighting strong cash generation capabilities. The operating cash flow to net income ratio of 1.36 indicates efficient cash conversion from earnings. The free cash flow to net income ratio of 0.91 further underscores the company's strong cash flow position.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2021
Income Statement
Total Revenue	65.45B	67.42B	60.33B	56.41B	52.81B	47.87B
Gross Profit	67.30B	62.19B	55.20B	51.34B	47.62B	43.33B
EBITDA	4.15B	5.88B	5.16B	4.54B	4.06B	3.35B
Net Income	2.78B	3.25B	2.73B	2.28B	2.11B	1.59B
Balance Sheet
Total Assets	72.19B	72.49B	66.36B	61.41B	58.63B	55.46B
Cash, Cash Equivalents and Short-Term Investments	0.00	26.46B	23.88B	30.84B	29.64B	31.68B
Total Debt	10.00B	15.05B	5.00B	5.00B	5.00B	5.03B
Total Liabilities	44.31B	44.42B	36.21B	33.22B	31.32B	29.74B
Stockholders Equity	27.88B	28.07B	29.90B	28.18B	27.32B	25.71B
Cash Flow
Free Cash Flow	0.00	5.81B	4.83B	3.57B	3.24B	3.07B
Operating Cash Flow	0.00	6.40B	5.67B	4.42B	4.46B	4.23B
Investing Cash Flow	0.00	-5.09B	-11.13B	-4.07B	-5.49B	-2.13B
Financing Cash Flow	0.00	271.00M	-1.34B	-212.00M	-112.00M	5.15B

Anicom Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1058.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8715, the sentiment is Positive. The current price of 1058 is below the 20-day moving average (MA) of 1261.15, below the 50-day MA of 1147.14, and above the 200-day MA of 904.99, indicating a bullish trend. The MACD of 63.34 indicates Negative momentum. The RSI at 67.03 is Neutral, neither overbought nor oversold. The STOCH value of 86.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8715.

Anicom Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8630	76 Outperform	¥5.40T	7.65	―	2.82%	11.37%	27.90%
8715	72 Outperform	¥100.13B	-6,185.63	―	0.82%	11.18%	-16.50%
8725	72 Outperform	¥5.92T	8.22	16.97%	2.59%	23.01%	2.59%
7326	69 Neutral	¥52.97B	19.36	6.16%	1.10%	13.99%	85.66%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
7157	67 Neutral	¥169.28B	22.15	―	―	20.22%	19.40%
8766	66 Neutral	¥11.48T	13.03	20.81%	3.33%	-2.10%	-8.76%

Anicom Holdings, Inc. Corporate Events

Anicom Shows Steady Pet Insurance Growth and Expands BioInsurTech Footprint in FY2025

Anicom Holdings reported monthly management indicators for its pet insurance and new business operations for fiscal 2025, highlighting steady growth in net premiums written and the number of policies in force compared with the previous year. Renewal rates remained in the high-88% range throughout the year, indicating stable customer retention and a solid recurring revenue base.

The company also disclosed expanding uptake of its Doubutsu Kenkatsu gut microbiota testing service and a rising portfolio of patents, metrics it positions as key to building a prevention-focused, data-driven business model. By publishing these parameters monthly, Anicom signals a commitment to transparency and underscores its strategy of using big data and BioInsurTech to differentiate in the pet insurance market and support long-term growth.

The most recent analyst rating on (JP:8715) stock is a Hold with a Yen1447.00 price target. To see the full list of analyst forecasts on Anicom Holdings, Inc. stock, see the JP:8715 Stock Forecast page.

Anicom’s Pet Insurance and Prevention Business Shows Steady Growth in January 2026

Anicom Holdings reported its monthly management parameters for January 2026, highlighting steady growth in its core pet insurance business, with net premiums written and policies in force increasing versus the previous year. Renewal rates remained robust in the high-80% range, underscoring solid customer retention and recurring revenue dynamics in its insurance portfolio.

The company also continued to expand its prevention-focused initiatives, including a rising number of applicants for its Doubutsu Kenkatsu gut microbiota testing program and an increase in patents held tied to its BioInsurTech strategy. These trends suggest ongoing investment in data-driven, preventive healthcare services for pets, supporting Anicom’s transition toward a prevention-oriented model and potentially enhancing its competitive differentiation in the pet insurance and health market.

The most recent analyst rating on (JP:8715) stock is a Buy with a Yen1282.00 price target. To see the full list of analyst forecasts on Anicom Holdings, Inc. stock, see the JP:8715 Stock Forecast page.

Anicom Holdings Posts Higher Revenue but Sharply Lower Profit for Nine-Month Period

Anicom Holdings reported recurring revenue of ¥54.99 billion for the nine months ended December 31, 2025, up 10.6% year on year, but recurring profit fell 41.2% to ¥2.23 billion and profit attributable to owners declined 44.6% to ¥1.43 billion. Despite modest growth in total assets and equity, profitability weakened markedly, with earnings per share dropping to ¥19.23, even as the company maintained its full-year forecast and signaled a slight year-on-year increase in annual dividends to ¥9 per share, highlighting pressure on margins but continued shareholder returns.

The company’s equity ratio remained essentially flat at around 39%, indicating a stable balance sheet in spite of profit erosion in the current period. Management is projecting full-year recurring revenue of ¥73.0 billion and profit attributable to owners of ¥2.1 billion, implying a continued decline in earnings versus the prior year, which may weigh on investor sentiment even as the unchanged guidance suggests no immediate deterioration beyond current expectations.

The most recent analyst rating on (JP:8715) stock is a Buy with a Yen1270.00 price target. To see the full list of analyst forecasts on Anicom Holdings, Inc. stock, see the JP:8715 Stock Forecast page.

Anicom Holdings Posts Steady Growth in Pet Insurance and Expands Preventive BioInsurTech Initiatives

Anicom Holdings reported its monthly management parameters for December 2025 and the fiscal year-to-date, highlighting steady growth in its pet insurance operations and prevention-focused initiatives. Net premiums written, policies in force, and renewal rates all improved compared with the previous year, indicating stable portfolio expansion and strong customer retention. The company also continued to increase the number of applicants for its “Doubutsu Kenkatsu” gut microbiota testing service and expanded its patent holdings, underscoring its strategic push into BioInsurTech and data-driven preventive healthcare, which supports its transition toward a prevention-oriented business model and may enhance its competitive positioning in Japan’s pet insurance market.

The most recent analyst rating on (JP:8715) stock is a Buy with a Yen1198.00 price target. To see the full list of analyst forecasts on Anicom Holdings, Inc. stock, see the JP:8715 Stock Forecast page.

Anicom Holdings Grows Revenue but Sees Sharp Profit Decline in Nine-Month Results

Anicom Holdings reported consolidated recurring revenues of ¥54,995 million for the nine months ended December 31, 2025, up 10.6% year on year, while recurring profit fell 41.2% to ¥2,228 million and profit attributable to owners of parent declined 44.6% to ¥1,426 million, reflecting pressure on margins despite topline growth; basic earnings per share dropped to ¥19.23. The company’s financial position remained broadly stable, with total assets of ¥73,478 million and an equity ratio of 38.8%, and it maintained its full-year forecast for FY2025/26, projecting recurring revenue of ¥73,000 million and significant year-on-year declines in profit, alongside a planned increase in the annual dividend to ¥9.00 per share, signaling a commitment to shareholder returns despite weaker earnings.

The most recent analyst rating on (JP:8715) stock is a Buy with a Yen1198.00 price target. To see the full list of analyst forecasts on Anicom Holdings, Inc. stock, see the JP:8715 Stock Forecast page.